CML, Chronic PhasePhase 2PEARLNCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
A Phase 2 study testing Asciminib and Nilotinib in people with CML, Chronic Phase and Chronic Myeloid Leukemia, Chronic Phase, run by Gruppo Italiano Malattie EMatologiche dell'Adulto at 11 sites in Spain.
Trial summary
A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive
- What is being tested?
- Asciminib and Nilotinib
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 11 sitesSpain
- Study dates
- 26 Jun 2025to Jun 2032
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Cytogenetic and molecular confirmed diagnosis of Ph+ and BCR::ABL1+ CML
- Age ≥ 18 years
- Early chronic phase, less than 3 months from diagnosis
- Evidence at the time of study entry of typical BCR::ABL1 RNA transcripts e13a2 or e14a2 (b2a2 or b3a2), which are required for BCR::ABL1 international scale reporting
- Prior treatment with any TKI for 30 days or less; prior treatment with hydroxyurea or anagrelide is allowed
- ECOG performance status of 0, 1 or 2
Show all 9Show fewer
- Adequate end organ function as defined by Total bilirubin ≤ 1.5 x ULN except for patients with Gilbert's syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN Aspartate transaminase (AST) ≤ 3.0 x ULN Alanine transaminase (ALT) ≤ 3.0 x ULN Serum amylase ≤ ULN Serum lipase ≤ ULN Alkaline phosphatase ≤ 2.5 x ULN, unless considered tumor related Creatinine clearance > 50 ml/min using Cockcroft-Gault formula
- Signed written informed consent according to ICH/EU/GCP and national local laws prior to any study procedure
- An effective form of contraception with their sexual partners from enrolment through 30 days after the end of treatment
Who cannot join
- CML in blast phase (BP) or in second chronic phase after previous BP, according to WHO criteria
- Previous treatment with TKIs for more than 30 days
- Refusal or impossibility to give an informed consent
- History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease, including any of the following: recent myocardial infarction (within last 6 months), uncontrolled congestive heart failure, unstable angina (within last 6 months), clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker).
- Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection)
- History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
Show all 12Show fewer
- History of acute or chronic liver disease
- History of other active malignancy within 2 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis B (HBV), or Hepatitis C (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) and Hepatitis B core antibody (HBc Ab / anti HBc) will be performed at study entry
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
- Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 30 days after the end of treatment
Trial locations and contacts
11 sites in 1 country. Contact the study team or a site near you to ask about taking part.
11 sites in 1 country
Spain11 sites, 11 recruiting
- Recruiting
Hospital del Mar (Barcelona)
Barcelona
Patricia Vélez Tenza
- Recruiting
Hospital Universitario Basurto
Bilbao
Fernando Marco de Lucas
- Recruiting
Institut Català d'Oncologia Girona
Girona
Anna Angona Figueras
- Recruiting
Hospital Virgen de las Nieves
Granada
José Manuel Puerta
- Recruiting
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria
Maria Teresa Gómez Casares
- Recruiting
Hospital Gral U. Gregorio Marañón
Madrid
Santiago Osorio
- Recruiting
Hospital Universitario 12 de Octubre
Madrid
Gonzalo Carreño Gómez-Tarragona
- Recruiting
Hospital Universitario La Paz
Madrid
María Raquel de Paz Arias
- Recruiting
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia
Raul Perez Lopez
- Recruiting
Complejo Asistencial Universitario de Salamanca
Salamanca
Magdalena Sierra Pacho
- Recruiting
Hospital Universitario La Fe Valencia
Valencia
Elvira Mora
About this study
Official title: Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B).
All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued.
Read more
During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily.
The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.
Read the detailed description
A phase 2, prospective, interventional, randomized (two arms, randomization 1:1), unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B).
- In the arm A, asciminib 80 mg QD will be given as single-agent. In the arm B, asciminib 80 mg QD will be started, then after 90 days asciminib will be given 40 mg BID and nilotinib 300 mg BID, or 300 mg OAD according to the presence/absence of asciminib adverse events, will be added-on in all patients. All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. In both arms the study drugs may be discontinued at any time for inefficacy (failure) or safety reasons(grade 3-4 toxicity or persistent grade 2 non hematologic toxicity). However, all the patient will remain "in study" (regular follow-up information will be required). The dose adjustments for toxicity and detailed criteria for treatment discontinuation (asciminib in arm A; asciminib or nilotinib in arm B) are specified within the protocol.
- After the induction of a DMR, the residual disease will be closely monitored by Q-PCR until the fourth year (consolidation phase). During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily.
- The patients maintaining a stable MR4 up to the end of the fourth year, that must include in the last year at least 3 evaluable QPCR analyses, will enter the treatment free remission (TFR) phase of the study and will discontinue the treatment (TFR phase). A single unconfirmed loss of MR4 will not preclude the possibility of treatment discontinuation. In case of confirmed loss of MR3 after discontinuation, the choice of subsequent treatment will be up to Local Investigators. The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.
- Conditions
- CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
- Being tested
- Asciminib, Nilotinib
- Keywords
- asciminib, nilotinib
- Medical subject headings
- Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AsciminibDrug
both arms will include asciminib treatment
NilotinibDrug
in the arm B the nilotinib will be added on in all patients
| Study group | Role | What they receive |
|---|---|---|
| Asciminib single agent | Experimental | Core phase (2 years): asciminib 80 mg QD will be given as single-agent.
Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 80 mg QD.
Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment Receives: Drug: Asciminib |
| Asciminib plus nilotinib | Experimental | Core phase (2 years): asciminib 80 mg QD will be started, then after 90 days asciminib will be given 40 mg BID and nilotinib 300 mg BID, or 300 mg OAD according to the presence/absence of asciminib adverse events, will be added-on.
Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 40 mg BID and nilotinib reduced to 300 mg daily.
Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment Receives: Drug: Asciminib; Drug: Nilotinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
evaluation of response of asciminib single-agent or in combination with nilotinib
Rate of deep molecular response (MR4) achievement
Measured: at 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2024
- Study start26 Jun 2025
- Primary completionJun 2029 (estimated)
- Study completionJun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CML, Chronic PhaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Sponsor type
- University, hospital or other
- Collaborators
- Grupo Español de Leucemia Mieloide Crónica
- Responsible party
- Sponsor
- Investigators
- Fausto Castagnetti, Principal investigator, "Seragnoli" Institute of Hematology Bologna (Italy)Valentin Garcia Gutierrez, Principal investigator, Hematology Unit, Hospital Universitario Ramón y Cajal, Madrid (Spain)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06409936
- Sponsor's protocol ID
- CML1624
- Acronym
- PEARL
- Status last verified
- Jul 2025
- First submitted
- 7 May 2024
- Last updated
- 8 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No